Table 2.
Results obtained in patients with medullary thyroid carcinoma with kinase inhibitors.
| Author | Patients (n) | PR (%) | SD >6 months (%) | Median PFS (months) | Median OS (months) | Dose reduction for toxicity (%) | Withdrawalfor toxicity (%) | |
| Vandetanib | Wells (2010)Robinson (2010)Wells (2010) | 3019331 | 30/20 c1644 | 53NE53 | 27.9NE30.5 (v) vs. 19.3 (placebo) | NE10>36 | 731535 | 231112 |
| Cabozantinib | Kurzrock (2010) | 34 | 50/29 c | 44 | ||||
| Motesanib | Schlumberger (2009) | 83 | 2 | 43 | 11 | NE | NE | NE |
| Axitinib | Cohen (2008) | 11 | 18 | 27 | 17 | >36 | 38 | 13 |
| Sunitinib | De Souza (2010)Carr (2010) | 256 | 3250 | 4633 | NENE | NENE | NENE | |
| Sorafenib | Kober (2007)Lam (2010) | 519 | 4010 | aaa43 | aaa17.9 | aaaNE | aaa76 | aaa16 |
| Pazopanib | Bible (2010) | 14 | 7 | 57 | ||||
| Imatinib | DeGroot (2007)Frank-Raue (2007) | 159 | 00 | 2756 | 27 | 20 |
PFS = progression-free survival, OS = overall survival, c = confirmed; NE = not evaluated.